HI-TECH PHARMACAL (NASDAQ:HITK)

View All ReportsStreetInsider.com Reports on HITK

Sep 10, 2009 11:30 AM FTN Equity Downgrades Hi-Tech Pharmacal (HITK) from Buy

Sep 9, 2009 12:14 PM Unusual 11 Mid-Day Movers 9/9: ENCO, VVUS, CLZR, HITK, DPTR Higher; OPXA, LRN, ROSG, ELOS Lower

Sep 9, 2009 09:34 AM Morning Movers 9/9: ENCO, VVUS, CLZR, WAVX, HITK, ISTA Higher; HNAB, ENWV, UWBK, AVAV, PBY Lower

Sep 9, 2009 08:18 AM Hi-Tech Pharmacal (HITK) Reports Surge in Q1 Sales and EPS

Jul 14, 2009 12:10 PM Unusual 11 Mid-Day Movers 7/14: HITK, NOVN, NSU, IMMU Higher; SBGI, CPF, HNT, COBZ Lower

View All Press ReleasesCompany Press Releases on HITK

Nov 16, 2009 09:00AM Hi-Tech Pharmacal's ECR Subsidiary Signs Exclusive Agreement to Commercialize Sleep Aid in Oral Spray Form

Nov 13, 2009 08:02PM Semi-Annual Changes to the NASDAQ Biotechnology Index

Oct 30, 2009 03:24PM Hi-Tech Pharmacal to Present at the 20th Annual Oppenheimer Healthcare Conference

StreetInsider Reports on HITK by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on HITK

Oct 26, 2009 03:15 AM 19 'Babies with Bathwater' and 1 'Dog with Fleas' Stocks for the Week

Sep 10, 2009 04:47 AM 16 Breakout Stocks on Unusually High Volume

Sep 9, 2009 04:29 PM Closing Update for Wednesday, Sept. 9

Aug 28, 2009 04:49 AM Mylan: Generic Drugmaker with a Strong Portfolio

Aug 5, 2009 04:47 AM Tracking Healthcare Trends and More

View All FilingsSEC Filings on HITK

Nov 16, 2009 06:13PM Form 4 HI TECH PHARMACAL CO For: Nov 12 Filed by: SELTZER REUBEN

Nov 16, 2009 04:34PM Form 4 HI TECH PHARMACAL CO For: Nov 12 Filed by: HIRSHAUT YASHAR

Nov 16, 2009 01:13PM Form 4 HI TECH PHARMACAL CO For: Nov 12 Filed by: Harvey Bryce M

Nov 16, 2009 12:31PM Form 4 HI TECH PHARMACAL CO For: Nov 12 Filed by: Simpson Bruce W

Nov 16, 2009 12:29PM Form 4 HI TECH PHARMACAL CO For: Nov 12 Filed by: Van Hulst Jack

Comments on recent HITK articles

toddschaus
on Sep 15, 2009
at 08:46 PM HITK underpriced and deserving further analysis I am a CPA veteran and stock analysis enthusiast that has been actively researching and following HITK for a long time. Sales, margins, and net profits for the company are growing off the charts over the past 6 months. They appear to have quietly arrived in the generic drug industry as a competitor on a new level. The company's trailing PE of 15 includes $1.5M earnings for the 2nd and 3rd qtrs of the prior fiscal year........but these amounts don't appear very relevant considering consecutive record breaking quarters of $5M and $8M earnings for the more recent 4th qtr of last year and the 1st qtr of the current fiscal year. I have been listening and participating on the company quarterly conference calls and weighing their comments about the future. I believe they will be reporting $8M+ earnings for the next two qtrs (i.e. the 2nd & 3rd qtr of this fiscal year). Note - the 2nd & 3rd qtrs are historically the company's best qtrs considering it is flu season. Without considering other positive factors.....down economy (read more $$$ to be spent on generics), an aging population base, growth possibility for a company breaking out of its shell, I see the company as underpriced and the stock hitting 40-50 (still at a 15 PE) in the next 6 months as the upcoming 2nd and 3rd qtr earnings are released. What are your thoughts? Regards, Todd Schaus
Article: Hi-Tech Pharmacal (HITK) Reports Surge in Q1 Sales and EPS

toddschaus
on Sep 15, 2009
at 08:44 PM HITK underpriced and deserving further analysis I am a CPA veteran and stock analysis enthusiast that has been actively researching and following HITK for a long time. Sales, margins, and net profits for the company are growing off the charts over the past 6 months. They appear to have quietly arrived in the generic drug industry as a competitor on a new level. The company's trailing PE of 15 includes $1.5M earnings for the 2nd and 3rd qtrs of the prior fiscal year........but these amounts don't appear very relevant considering consecutive record breaking quarters of $5M and $8M earnings for the more recent 4th qtr of last year and the 1st qtr of the current fiscal year. I have been listening and participating on the company quarterly conference calls and weighing their comments about the future. I believe they will be reporting $8M+ earnings for the next two qtrs (i.e. the 2nd & 3rd qtr of this fiscal year). Note - the 2nd & 3rd qtrs are historically the company's best qtrs considering it is flu season. Without considering other positive factors.....down economy (read more $$$ to be spent on generics), an aging population base, growth possibility for a company breaking out of its shell, I see the company as underpriced and the stock hitting 40-50 (still at a 15 PE) in the next 6 months as the upcoming 2nd and 3rd qtr earnings are released. What are your thoughts? Regards, Todd Schaus
Article: Hi-Tech Pharmacal (HITK) Reports Mixed Q3 Earnings

Comments on HITK

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?